Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...

Banks and other lenders are readying over €10B ($11.1B) in funding as New York-based buyout firm Clayton Dubilier & Rice and ...

The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising ...

In its third-quarter results update, Sanofi said the consumer health unit – which owns brands ... driven by its specialty care business and particularly immunology blockbuster Dupixent ...

Attorney General Bridget Hill announced a settlement with Sanofi-Aventis U.S. LLC (Sanofi), which guarantees that Wyoming residents not enrolled in government health care programs can buy Sanofi’s ins ...

To mark Rare Disease Day, Sanofi has collaborated ... our vision for Better Care for Rare.” There has been much research into the potential link between music and health and studies have shown ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Tandem Diabetes Care (TNDM – Research Report). Sanofi ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...

(Bloomberg) -- Sanofi has received binding offers for its consumer health ... rank among the largest deals in Europe this ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National ... All patients were on background maximal standard-of-care inhaled therapy. Dupixent significantly reduced COPD ...

in funding as New York-based buyout firm Clayton Dubilier & Rice and its French rival PAI Partners compete for Sanofi’s (NASDAQ:SNY) consumer healthcare spinoff, Bloomberg reported Tuesday.